GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Piotroski F-Score

Gilead Sciences (Gilead Sciences) Piotroski F-Score

: 7 (As of Today)
View and export this data going back to 1992. Start your Free Trial

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gilead Sciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Gilead Sciences's Piotroski F-Score or its related term are showing as below:

GILD' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Gilead Sciences was 8. The lowest was 4. And the median was 6.


Gilead Sciences Piotroski F-Score Historical Data

The historical data trend for Gilead Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 5.00 6.00 7.00 7.00

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 8.00 8.00 8.00 7.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Piotroski F-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 1010 + 1045 + 2180 + 1429 = $5,664 Mil.
Cash Flow from Operations was 1744 + 2338 + 1755 + 2169 = $8,006 Mil.
Revenue was 6352 + 6599 + 7050 + 7114 = $27,115 Mil.
Gross Profit was 4951 + 5157 + 5485 + 5024 = $20,617 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(63171 + 61876 + 62337 + 62373 + 62125) / 5 = $62376.4 Mil.
Total Assets at the begining of this year (Dec22) was $63,171 Mil.
Long-Term Debt & Capital Lease Obligation was $23,189 Mil.
Total Current Assets was $16,085 Mil.
Total Current Liabilities was $11,280 Mil.
Net Income was 19 + 1144 + 1789 + 1640 = $4,592 Mil.

Revenue was 6590 + 6260 + 7042 + 7389 = $27,281 Mil.
Gross Profit was 5166 + 4818 + 5647 + 5993 = $21,624 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(67952 + 63080 + 62870 + 62557 + 63171) / 5 = $63926 Mil.
Total Assets at the begining of last year (Dec21) was $67,952 Mil.
Long-Term Debt & Capital Lease Obligation was $22,957 Mil.
Total Current Assets was $14,443 Mil.
Total Current Liabilities was $11,238 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gilead Sciences's current Net Income (TTM) was 5,664. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gilead Sciences's current Cash Flow from Operations (TTM) was 8,006. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=5664/63171
=0.0896614

ROA (Last Year)=Net Income/Total Assets (Dec21)
=4592/67952
=0.06757711

Gilead Sciences's return on assets of this year was 0.0896614. Gilead Sciences's return on assets of last year was 0.06757711. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Gilead Sciences's current Net Income (TTM) was 5,664. Gilead Sciences's current Cash Flow from Operations (TTM) was 8,006. ==> 8,006 > 5,664 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=23189/62376.4
=0.37175919

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=22957/63926
=0.35911836

Gilead Sciences's gearing of this year was 0.37175919. Gilead Sciences's gearing of last year was 0.35911836. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=16085/11280
=1.42597518

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=14443/11238
=1.28519309

Gilead Sciences's current ratio of this year was 1.42597518. Gilead Sciences's current ratio of last year was 1.28519309. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Gilead Sciences's number of shares in issue this year was 1255. Gilead Sciences's number of shares in issue last year was 1265. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=20617/27115
=0.76035405

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=21624/27281
=0.79263957

Gilead Sciences's gross margin of this year was 0.76035405. Gilead Sciences's gross margin of last year was 0.79263957. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=27115/63171
=0.42923177

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=27281/67952
=0.40147457

Gilead Sciences's asset turnover of this year was 0.42923177. Gilead Sciences's asset turnover of last year was 0.40147457. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+1+0+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gilead Sciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Gilead Sciences  (NAS:GILD) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Gilead Sciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (Gilead Sciences) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711

Gilead Sciences (Gilead Sciences) Headlines